Bristol Myers’s most recent trend suggests a bearish bias. One trading opportunity on Bristol Myers is a Bear Call Spread using a strike $52.50 short call and a strike $57.50 long call offers a potential 21.07% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $52.50 by expiration. The full premium credit of $0.87 would be kept by the premium seller. The risk of $4.13 would be incurred if the stock rose above the $57.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Bristol Myers is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Bristol Myers is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Bristol Myers
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma
Wed, 25 Apr 2018 20:20:00 +0000
Bristol-Myers Squibb Company today announced that the European Commission has approved an every four-week Opdivo monotherapy dosing schedule of 480 mg infused over 60 minutes as an option for patients with advanced melanoma and previously treated renal cell carcinoma.
Drug Maker Bristol-Myers Squibb Is Having a Bad Reaction to Selling
Wed, 25 Apr 2018 19:07:00 +0000
In this daily bar chart of BMY, below, we can see a temporary upside breakout in late February that was reversed in a few weeks. The daily On-Balance-Volume (OBV) line peaked in the middle of February and turned lower signaling that sellers of BMY had become more aggressive. In this weekly bar chart of BMY, below, we went back five years to get a better perspective on things.
How Analysts Rate Bristol-Myers Squibb in 1Q18
Wed, 25 Apr 2018 15:15:10 +0000
Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18. Also, the earnings per share are expected at $0.85 for 1Q18. The revenue growth is expected to be driven by the prioritized brands including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy, partially offset by lower sales of established brands.
Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX
Wed, 25 Apr 2018 14:56:02 +0000
Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.
Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18
Wed, 25 Apr 2018 13:45:08 +0000
As discussed, Bristol-Myers Squibb (BMY) is expected to report growth of ~6.3% to $5.2 billion in its 1Q18 earnings on April 26. The above graph shows the quarterly revenues of Bristol-Myers Squibb since 1Q17 and analysts’ estimates for 1Q18. Nearly 45% of total revenues for Bristol-Myers Squibb come from international sales, so the company is exposed to currency risk.
Also on Market Tamer…
Follow Us on Facebook